Immunyx Pharma

Immunyx Pharma is a healthcare startup committed to revolutionizing immune modulation by targeting neutrophil toxicity in a range of chronic diseases. The team, comprised of leading experts in neutrophil biology and nanoparticle delivery, has developed a targeted neutrophil nanoparticle platform (TENNs) to address challenges in neutrophil therapy. While major pharmaceutical companies have heavily invested in neutrophil-targeted drugs, they have struggled to bring effective solutions to the clinic due to the risk of neutropenia and the complexity of modulating this dynamic cell population. The TENN platform aims to manipulate neutrophil toxic behavior without compromising their disease-fighting function, delivering a concentrated drug payload that remains bioavailable for an extended period throughout the body. Currently, the company's focus lies in applying this platform to modulate neutrophil activity in cancer and inflammatory diseases.